90857-97-9

Upstream product

• 90857-84-4 1-[(4-methoxyphenyl)diphenylmethoxy]-3-(3-tetradecylphenoxy)-2-propanol 
• 22165-05-5 4-methoxy-1-tetradecylbenzene 
• 25401-89-2 4-n-tetradecylphenol 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 108-24-7 acetic anhydride 
• 14470-28-1 mono-4-methoxytrityl chloride 
• 90857-77-5 2,2-dimethyl-4-<(4-tetradecylphenoxy)methyl>-1,3-dioxolane 
• 90857-81-1 3-(3-tetradecylphenoxy)-1,2-propanediol 

Downstream Products

• 90858-00-7 4-hydroxy-N,N,N-trimethyl-9-oxo-7-[(3-tetradecylphenoxy)methyl]-3,5,8-trioxa-4-phosphadecan-1-aminium 4-oxide, hydroxide, inner salt 
• 90857-99-1 2-bromoethyl 2-(acetyloxy)-3-(3-tetradecylphenoxy)propyl phosphate 
• 90857-98-0 1-hydroxy-3-(3-tetradecylphenoxy)propan-2-yl acetate 

Relevant academic research and scientific papers

SULFUR INHIBITORS OF PHOSPHOLIPASE A-Z

Phospholipase A2 inhibitors having the formula wherein R" is a C2-C20 alkyl group, R1" is a C1-C4 alkyl group, y is an integer from 2 to 10, and J- is a pharmaceutically acceptable anion, are described

Antihypertensive phosphate derivatives

Antihypertensive phosphate derivatives having the following formula are described: STR1 wherein X is selected from one or more of: (a) C1 -C24 branched or straight chain alkyl; (b) C1 -C24 branched or straight chain alkoxy; (c) STR2 wherein n and m are integers from 0 to 25 and the sum of n and m is less than or equal to 25; phenyl; substituted phenyl wherein the substituents are selected from the group consisting of C1 -C20 branched or straight chain alkyl, C1 -C20 branched or straight chain alkoxy, halogen, trifluoromethyl, phenyl, and substituted phenyl, phenoxy; and substituted phenoxy, wherein the substituents are selected from the group consisting of C1 -C20 branched or straight chain alkyl, halogen, trifluoromethyl, phenyl and substituted phenyl; Q is selected from the group consisting of: STR3 wherein R1 is selected from the group consisting of hydrogen, C1 -C4 branched or straight chain alkyl, C1 -C4 branched or straight chain alkoxy and C1 -C4 branched or straight chain alkylamino and wherein R3 is C1 -C4 alkyl, with the proviso that when Q is STR4 then R1 is C1 -C4 branched or straight chain alkyl; T is a bivalent radical selected from the group consisting of --(CHR)p -- and STR5 wherein p is an integer from 1 to 15, the moiety --(CHR)p -- represents an alkylene chain substituted at any position with one or more C1 -C10 alkyl groups or phenyl groups, and the moiety STR6 is bound with the oxygen atom attached directly to the aromatic ring; and Z is STR7 wherein R2 is hydrogen or C1 -C4 branched or straight chain alkyl and q is an interger from 4 to 7; in either the racemic or optically active forms.

Analogues of platelet activating factor (PAF). I. Some modifications of the alkoxy chain

Analogues of platelet activating factor (PAF) in which the ether oxygen has been removed and in which the alkoxy chain at C1 has been replaced with a o-, p-, or m-alkylphenoxy group (30, 31, and 35, respectively) have been prepared. Compound 6 shows reduced platelet aggregation and hypotensive activity in comparison with C16 and C18 PAF. The results obtained for compounds 30, 31, and 35 indicate that the hypotensive and platelet aggregating responses are sensitive to structural modification of the ether chain. The ortho analogue 30 shows no platelet aggregating activity and only a weak hypotensive response. The para analogue 31 exhibits a moderate decrease in activity in both assays. The meta analogue 35 is the most active of the three.